Principal Investigator
更新時間：2023-09-19
- Co-Principal Investigator
- Clinical Trial Experience (year) 12 years 9 個月
-
jenny5290204@gmail.com
Highlights
The prescription of anticoagulants for patients diagnosed with or on high risk for thromboembolic disorders is a common clinical practice. The efficacy of anti-coagulants can benefit the patients by reducing the arterial and deep vein thrombosis, nevertheless also can cause the inherited risks for bleeding. There are four popular new oral anticoagulants (NOACs, i.e., apixaban, dabigatran, edoxaban, and rivaroxaban) that cover common clinical indications. Not uncommonly, patients encountered bleeding side effect on usage of certain NOAC. However, the physicians are unable to know which NOAC is the better or best choice for the patient. The application of state-of-the-art genetics technology, we believe, will help physician to achieve the Precise Prescription of Anti-coagulants.
Study Area
- Cardiovascular
- Cardiac lipotoxicity
- VLDL
- mechanisms of arrhythmias
- Precise Prescription
Professional Experiences
Attending physician
Cardiovascular Medicine
2004-2021
Associate Professor
Internal Medicine
2019- 迄今
Education
Faculty of Medicine
Medical Doctor
1992-1999
Graduate Institute of Medicine
Master of Science
2003-2005
Graduate Institute of Medicine
Ph.D.
2008-2016
Clinical Trials List
2016
Total 13
-
I 0
-
I/II 0
-
II 3
-
II/III 1
-
III 9
-
IV 0
-
Others 0
Number of Studies by Scale
0件
Taiwan Multiple Center
Taiwan Single Center
0Cases
Taiwan Multiple Center
0Cases
Multi-Regional Multi-Center
12Cases
